The purpose of this study is to investigate a potential new treatment for autoimmune diseases such as Atopic dermatitis. Atopic dermatitis leads the skin conditions with the highest worldwide disability burden, and it is second only to acne as the most common skin condition treated by dermatologists. Current treatment options often only have a moderate impact, and there is a need for more efficient treatments.
For this initial stage of research, we require healthy participants to assess to safety and tolerability of the medication, how it is absorbed in the bloodstream, and whether you develop antibodies to the drug. If this study is successful, in later stages the medication will be tested with people who have atopic dermatitis. There is evidence that there are differences in the way that Asian populations and Caucasian populations process drugs.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!